In the study, funded in part by the Israel Cancer Association Research and the Israel Science Foundation, Wolf and his colleagues used breast cancer samples collected from the breast and the liver ...

we invited the director of the oncology department at the Ichilov Hospital, Prof. Ido Wolf, to the "Expert Clinic" studio to ask what we must know about cancer today - and what the future holds ...

Ido Wolf, director of oncology at Ichilov. “The collaboration with C2i Genomics will provide us a unique opportunity to be world leaders in a field that is definitely one of the most important and ...

These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.

The study was conducted and published by a team of researchers led by Dr. Tami Rubinek, Head of the Oncology Research Lab, and Prof. Ido Wolf, MD, Head of Oncology Division, Tel Aviv Medical ...

However, most of our patients limit their daily activities in ways that run counter to this goal," said Professor Ido Wolf, Head of the Oncology Division at the Sourasky Medical Center.

Ido Wolf, MD, head, oncology division, Tel Aviv Sourasky Medical Centre; professor of oncology, faculty of medicine, Tel Aviv University; and head, National Israeli Council for Prevention ...

IDO, which catalyzes the breakdown of the essential amino acid tryptophan, has emerged as a key target in cancer immunotherapy because of its role in enabling cancers to evade the immune system (Nat.

This comes after a series of trial hits, with NewLink suffering a setback in its immuno-oncology pipeline just this week after its IDO inhibitor indoximod, touted as the next big thing in cancer ...